pBK-YE1-BE3 Citations (3)
Originally described in: Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions.Kim YB, Komor AC, Levy JM, Packer MS, Zhao KT, Liu DR Nat Biotechnol. 2017 Feb 13. doi: 10.1038/nbt.3803. PubMed Journal
Articles Citing pBK-YE1-BE3
| Articles |
|---|
| Correction of the Marfan Syndrome Pathogenic FBN1 Mutation by Base Editing in Human Cells and Heterozygous Embryos. Zeng Y, Li J, Li G, Huang S, Yu W, Zhang Y, Chen D, Chen J, Liu J, Huang X. Mol Ther. 2018 Nov 7;26(11):2631-2637. doi: 10.1016/j.ymthe.2018.08.007. Epub 2018 Aug 14. PubMed |
Treatment of a metabolic liver disease by in vivo genome base editing in adult mice.
Villiger L, Grisch-Chan HM, Lindsay H, Ringnalda F, Pogliano CB, Allegri G, Fingerhut R, Haberle J, Matos J, Robinson MD, Thony B, Schwank G.
Nat Med. 2018 Oct;24(10):1519-1525. doi: 10.1038/s41591-018-0209-1. Epub 2018 Oct 8.
PubMed
Associated Plasmids |
| Base editing strategy for insertion of the A673T mutation in the APP gene to prevent the development of AD in vitro. Guyon A, Rousseau J, Begin FG, Bertin T, Lamothe G, Tremblay JP. Mol Ther Nucleic Acids. 2021 Mar 1;24:253-263. doi: 10.1016/j.omtn.2021.02.032. eCollection 2021 Jun 4. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.